There is human Selank research, but the existence of a clinical paper is not the same as strong evidence for every anxiety claim. The useful question is what the study design can establish, how precisely the result is reported and whether it applies to the person seeking treatment.
A 2014 comparative study examined Selank and phenazepam in sixty patients with anxiety-spectrum or somatoform diagnoses. The English abstract reports anxiety-related benefits and effects on quality of life. It does not provide the detail needed here to independently assess allocation, masking, attrition or the size and uncertainty of each treatment difference.
Those omissions matter. A favorable conclusion can coexist with uncertainty about how much of an observed change is attributable to the intervention. Comparing active treatments also requires careful interpretation of the study’s intended hypothesis. Similar-looking outcomes do not establish formal equivalence unless the design and analysis were built to test that question with an appropriate margin.
The patient group should not be flattened into a universal category of stress. Everyday worry, a diagnosed anxiety disorder and symptoms arising from another illness or medicine can require different assessment. Evidence from one selected group cannot automatically predict benefit in all three situations.
Another important distinction is symptom change versus a complete treatment decision. A clinician weighs severity, functional impairment, prior care, preferences and risks alongside any reported average effect. An abstract cannot supply that individual assessment. Nor can it validate a separately sourced product simply because its label contains the same name.
For readers comparing Selank with established care, the evidence would become more informative with transparent, adequately controlled trials reporting patient-important outcomes and sufficient safety follow-up. That is a description of what is needed, not a claim that the published result is worthless or that every participant’s experience was explained by expectation.
This appraisal is limited to the English abstract of a Russian-language primary paper. It supports a cautious statement that Selank has been studied clinically for anxiety-related conditions. It does not justify calling it a proven replacement for prescribed treatment, a predictable solution for all anxiety or a product with a fully characterized benefit-risk profile.